文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

SQuID II:皮下胰岛素治疗糖尿病酮症酸中毒的临床与运营效果

SQuID (subcutaneous insulin in diabetic ketoacidosis) II: Clinical and operational effectiveness.
PubMed 文献 · Acad Emerg Med · 2024-09-23
一句话结论在低至中度糖尿病酮症酸中毒中,SQuID 方案的执行依从性高、安全性不劣于或优于静脉胰岛素,阴离子间隙关闭更快,急诊停留时间更短,ICU 收治率从 54% 降至 21% 以下。

这项在 urban academic hospital 开展的真实世界前瞻性观察性队列研究(2023年3月4日至2024年3月4日)纳入 84 例低至中度糖尿病酮症酸中毒患者,其中 62 例(74%)接受 SQuID(皮下胰岛素治疗糖尿病酮症酸中毒)方案、22 例(26%)接受静脉胰岛素。两组方案执行依从性均高;因低血糖需要给予补救葡萄糖的分别为 5 例(8%)与 4 例(18%)(差值 9%,-31% 至 10%)。与静脉胰岛素组相比,SQuID 组阴离子间隙关闭时间缩短 1.4 h(95%CI -3.4 至 0.2 h),方案执行时间缩短 10.4 h(95%CI -22.3 至 -5.0 h);SQuID 组急诊停留时间中位数 9.8 h(IQR 6.0-13.6)低于静脉胰岛素病房组 18.3 h(IQR 13.4-22.0 h),但长于整体静脉胰岛素队列。自 SQuID 实施以来,低至中度糖尿病酮症酸中毒的 ICU 收治率从 54% 降至 21% 以下(下降 33%)。作者认为 SQuID 方案已成为该院治疗低至中度糖尿病酮症酸中毒的默认路径。

要点

  • 84 例低至中度糖尿病酮症酸中毒患者中,62 例(74%)采用 SQuID 皮下胰岛素方案、22 例(26%)采用静脉胰岛素,两组方案执行依从性均高。
  • 因低血糖需补救葡萄糖者:SQuID 组 5 例(8%)vs 静脉胰岛素组 4 例(18%),差值 9%(-31% 至 10%)。
  • 与静脉胰岛素组相比,SQuID 组阴离子间隙关闭时间缩短 1.4 h(95%CI -3.4 至 0.2 h),方案执行时间缩短 10.4 h(95%CI -22.3 至 -5.0 h)。
  • 急诊停留时间中位数:SQuID 组 9.8 h(IQR 6.0-13.6)低于静脉胰岛素病房组 18.3 h(IQR 13.4-22.0 h),但长于整体静脉胰岛素队列。
  • 自 SQuID 实施以来,低至中度糖尿病酮症酸中毒的 ICU 收治率从 54% 降至 21% 以下,下降 33%。

适用人群与场景

  • 低至中度(LTM)糖尿病酮症酸中毒患者,本次研究将纳入范围扩大到病情更重者,并可收入普通内科病房
  • 真实世界研究场景:城市学术医院急诊科,研究期 2023年3月4日至2024年3月4日

处置流程与药物剂量

  • 静脉胰岛素组在病房或 ICU 接受治疗;SQuID 组按皮下胰岛素方案治疗,研究记录的执行依从性指标为至开始甘精胰岛素的时间与至开始含葡萄糖液体的时间

研究设计与关键结果

  • 真实世界前瞻性观察性队列研究,单中心,84 例低至中度糖尿病酮症酸中毒患者,62 例(74%)接受 SQuID、22 例(26%)接受静脉胰岛素。
  • 两组执行依从性均高;因低血糖需要补救葡萄糖者 SQuID 组 5 例(8%)vs 静脉胰岛素组 4 例(18%),差值 9%(-31% 至 10%)。
  • 与静脉胰岛素组相比,SQuID 组至阴离子间隙关闭时间缩短 1.4 h(95%CI -3.4 至 0.2 h),方案执行时间缩短 10.4 h(95%CI -22.3 至 -5.0 h)。
  • 急诊停留时间中位数 SQuID 组 9.8 h(IQR 6.0-13.6)低于静脉胰岛素病房组 18.3 h(IQR 13.4-22.0 h),但长于整体静脉胰岛素队列。
  • 自 SQuID 实施以来,低至中度糖尿病酮症酸中毒的 ICU 收治率从 54% 降至 21% 以下(下降 33%)。

证据类型、等级与局限

  • 证据类型:真实世界前瞻性观察性队列研究
  • 局限:原文报告为单中心研究

对床旁实践的改变

  • 作者认为,在低至中度糖尿病酮症酸中毒中,SQuID 方案执行依从性高、安全性不劣于或优于静脉胰岛素,临床与运营效果良好
  • 作者指出,SQuID 方案已成为该院治疗低至中度糖尿病酮症酸中毒的默认路径(de facto default pathway)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: We previously demonstrated safe treatment of low- to moderate-severity (LTM) diabetic ketoacidosis (DKA) using the SQuID protocol (subcutaneous insulin in DKA) in a non-intensive care unit (ICU) observation setting, with decreased emergency department length of stay (EDLOS). Here, we expand eligibility to include sicker patients and admission to a regular medical floor and collected more detailed clinical data in a near-real-time fashion.

METHODS: This is a real-world, prospective, observational cohort study in an urban academic hospital (March 4, 2023-March 4, 2024). LTM DKA patients were treated with IV insulin (floor or ICU) or on SQuID. We compare fidelity (time to glargine and dextrose-containing fluids), safety (rescue dextrose for hypoglycemia), effectiveness (time to anion gap closure, time on protocol), and operational efficiency (time to bed request, EDLOS, and ICU admission rate since implementation of the protocol).

RESULTS: Of 84 patients with LTM DKA, 62 (74%) of were treated with SQuID and 22 (26%) with IV insulin. Fidelity was high in both groups. Rescue dextrose was required in five (8%) versus four (18%) patients, respectively (difference 9%, -31% to 10%). Compared to the IV insulin group, time to anion gap was 1.4 h shorter (95% CI -3.4 to 0.2 h) and time on protocol was 10.4 h shorter (95% CI -22.3 to -5.0 h) in SQuID patients. Median EDLOS was lower in the SQuID cohort 9.8 h (IQR 6.0-13.6) than the IV floor cohort 18.3 h (IQR 13.4-22.0 h), but longer than the overall IV insulin cohort. Since inception of SQuID, ICU admission rate in LTM DKA has decreased from 54% to under 21%.

CONCLUSIONS: In this single-center study, we observed excellent fidelity, equivalent or superior safety, and clinical and operational effectiveness with SQuID compared to IV insulin. The SQuID protocol has become the de facto default pathway for treatment of LTM DKA. Since inception of SQuID, ICU admissions in LTM DKA have decreased 33%.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Griffey RT, Schneider RM, Girardi M, et al. SQuID (subcutaneous insulin in diabetic ketoacidosis) II: Clinical and operational effectiveness. Acad Emerg Med. 2024. PMID: 39308229. doi:10.1111/acem.15020

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。